Luye Pharma Group Ltd.
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04381910
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China
A Study to Evaluate LY01011 and Xgeva® in Healthy Adults
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT04198636
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04088604
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04045678
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, China
A Study of LY03003 in Patients With Early-stage Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04044547
A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03844438
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Relative Bioavailability Food Effect Study of LY03005
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT03822065
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT03785652
- Locations
- 🇨🇳
Approval Letter of Ethics Committee of The Sixth Hospital of Peking University, Haidian District,, Beijing, China
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03751488
- Locations
- 🇺🇸
Collaborative Neuroscience Network LLC, Garden Grove, California, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03733561
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States